Virulizin is an immunotherapy drug preparation that is thought to stimulate the patient's immune system, which in turn may slow the growth of tumors. It is presented in vials as a sterile preparation for IM injection. The purpose of the trial is to investigate if Virulizin in combination with gemcitabine provides better efficacy than gemcitabine alone (with placebo) against pancreatic cancer.Virulizin® efficacy will continue to be assessed if chemotherapy is changed to 5-Fluorouracil.

开始日期2002-07-01

申办/合作机构

Aptose Biosciences, Inc.

100 项与 Virulizin 相关的临床结果

登录后查看更多信息

100 项与 Virulizin 相关的转化医学

登录后查看更多信息

100 项与 Virulizin 相关的专利（医药）

登录后查看更多信息

项与 Virulizin 相关的文献（医药）

2021-08-01·Cancer Medicine3区 · 医学

Interleukin‐25: New perspective and state‐of‐the‐art in cancer prognosis and treatment approaches

3区 · 医学

ReviewOA

作者: Olegovna Zekiy, Angelina ; Gholizadeh Navashenaq, Jamshid ; Amir, Azwar ; Gowhari Shabgah, Arezoo ; Ebrahimi Nik, Maryam ; Ahmadi, Majid ; Gardanova, Zhanna R. ; Thangavelu, Lakshmi

AbstractCancer is a leading cause of death which imposes a substantial financial burden. Among the several mechanisms involved in cancer progression, imbalance of immune cell‐derived factors such as cytokines and chemokines plays a central role. IL‐25, as a member of the IL‐17 cytokine subfamily, exerts a paradoxical role in cancer, including tumor supportive and tumor suppressive. Hence, we have tried to clarify the role of IL‐25 and its receptor in tumor progression and cancer prognosis. It has been confirmed that IL‐25 exerts a tumor‐suppressive role through inducing infiltration of eosinophils and B cells into the tumor microenvironment and activating the apoptotic pathways. In contrast, the tumor‐supportive function has been implemented by activating inflammatory cascades, promoting cell cycle, and inducing type‐2 immune responses. Since IL‐25 has been dysregulated in tumor tissues and this dysregulation is involved in cancer development, its examination can be used as a tumor diagnostic and prognostic biomarker. Moreover, IL‐25‐based therapeutic approaches have shown promising results in cancer inhibition. In cancers in which IL‐25 has a tumor‐suppressive function, employing IL‐25‐enhancing approaches, such as Virulizin® and dihydrobenzofuran administration, has potentially inhibited tumor cell growth. On the other hand, in the case of IL‐25‐dependent tumor progression, using IL‐25 blocking methods, including anti‐IL‐25 antibodies, might be a complementary approach to the other anticancer agent. Collectively, it is hoped, IL‐25 might be a promising target in cancer treatment.

2008-12-01·Cancer Immunology, Immunotherapy2区 · 医学

Virulizin® induces production of IL-17E to enhance antitumor activity by recruitment of eosinophils into tumors

2区 · 医学

Article

作者: Tania Benatar ; Sandy Der ; Xiaoping Gu ; Vivian Lee ; Jeff Lightfoot ; Hui Li ; Ningping Feng ; Ming Wang ; Jim A. Wright ; Ming Y. Cao ; Aiping H. Young ; Yoon Lee ; Hongnan Jin

Virulizin has demonstrated strong antitumor efficacy in a variety of human tumor xenograft models including melanoma, pancreatic cancer, breast cancer, ovarian cancer and prostate cancer. Our previous studies have demonstrated that macrophages, NK cells, and cytokines are important in the antitumor mechanism of Virulizin. Virulizin treatment of tumor bearing mice results in the expansion as well as increased activity of monocytes/macrophages and production of cytokines IL-12 and TNFalpha and activation of NK cells. In this study we show that the inflammatory cytokine IL-17E (IL-25) is induced by Virulizin treatment and is part of its antitumor mechanism. IL-17E is a proinflammatory cytokine, which induces a T(H)2 type immune response, associated with eosinophil expansion and infiltration into mucosal tissues. IL-17E was increased in sera of Virulizin-treated mice bearing human melanoma xenografts, compared to saline-treated controls, as shown by 2D gel electrophoresis and ELISA. Treatment of splenocytes in vitro with Virulizin resulted in increased IL-17E mRNA expression, which peaked between 24 and 32 h post-stimulation. Both in vitro and in vivo experiments demonstrated that B cells produced IL-17E in response to Virulizin treatment. Furthermore, Virulizin treatment in vivo resulted in increased blood eosinophilia and eosinophil infiltration into tumors. Finally, injection of recombinant IL-17E showed antitumor activity towards xenografted tumors, which correlated with increased eosinophilia in blood and tumors. Taken together, these results support another antitumor mechanism mediated by Virulizin, through induction of IL-17E by B cells, leading to recruitment of eosinophils into tumors, which may function in parallel with macrophages and NK cells in mediating tumor destruction.

2007-10-01·International Immunopharmacology2区 · 医学

Virulizin®, a novel immunotherapy agent, stimulates TNFα expression in monocytes/macrophages in vitro and in vivo

2区 · 医学

Article

作者: Xiaoping Gu ; Hongnan Jin ; Sandy Der ; Vivian Lee ; Ming Y. Cao ; Aiping H. Young ; Yoon Lee ; Ming Wang ; Jim A. Wright ; Pu Liu ; Ningping Feng ; Tania Benatar ; Jeff Lightfoot ; Hui Li

Virulizin, a novel biological response modifier, has demonstrated broad antitumor efficacy in a variety of human tumor xenograft models including melanoma, pancreatic cancer, breast cancer, ovarian cancer and prostate cancer. Previous studies have demonstrated a significant role of macrophages and NK cells in the antitumor mechanism of Virulizin. Increased activity and expansion of macrophages and NK cells has been observed in mice treated with Virulizin. In the present study, the effects of Virulizin on TNFalpha expression were investigated in vitro and in vivo. CD-1 nude mice were treated with Virulizin daily for 5 days. Quantitative RT-PCR demonstrated that the level of TNFalpha mRNA increased in peritoneal macrophages isolated from Virulizin-treated mice as compared to the control group. An increase in TNFalpha protein expression was also observed, as assessed by flow cytometric analysis. Increased levels of TNFalpha mRNA were seen in human tumor xenografts following treatment of tumor-bearing mice with Virulizin. In the presence of LPS, Virulizin also stimulated TNFalpha protein secretion and mRNA expression in human monocytic U937 cells and mouse macrophage RAW264.7 cells in vitro in a time- and dose-dependent manner. U937 cells treated with Virulizin showed a significantly enhanced cytotoxicity that was eliminated upon neutralization of TNFalpha. Virulizin also induced the phosphorylation of IkappaB, suggesting that induction of TNFalpha expression by Virulizin is mediated by activation of NFkappaB. The results indicate that Virulizin-induced TNFalpha expression contributes to modulation of immune responses and antitumor activities.

100 项与 Virulizin 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	L03A	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
结直肠癌	墨西哥	-	1997-01-01
卡波西肉瘤	墨西哥	-	1997-01-01
黑色素瘤	墨西哥	-	1997-01-01
胰腺癌	墨西哥	-	1997-01-01
肾细胞癌	墨西哥	-	1997-01-01
胃癌	墨西哥	-	1997-01-01
宫颈癌	墨西哥	-	1997-01-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
乳腺癌	临床2期	加拿大	-	-
肾肿瘤	临床2期	加拿大	-	-
肺癌	临床2期	加拿大	-	-
黑色素瘤	临床2期	加拿大	-	-
卵巢癌	临床2期	加拿大	-	-
胃癌	临床2期	加拿大	-	-
宫颈癌	临床2期	加拿大	-	-
结直肠癌	临床1期	加拿大	-	-
卡波西肉瘤	临床1期	加拿大	-	-
胰腺癌	临床前	-	Aptose Biosciences, Inc.	2002-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2006	临床3期	胰腺癌	434	Virulizin + Gemcitabine	(夢繭鹽窪築襯醖構築廠) = 蓋醖鬱願鏇鹽鑰獵網築餘鏇繭膚願製齋鹽鹽糧 (齋餘觸遞醖製築顧簾積 )	-	2006-06-20
				Placebo + Gemcitabine	(夢繭鹽窪築襯醖構築廠) = 獵觸遞積簾襯夢獵襯壓餘鏇繭膚願製齋鹽鹽糧 (齋餘觸遞醖製築顧簾積 )